IL1B and metabolic dysfunction-associated steatohepatitis: The pan-caspase inhibitors, Vx-166 and Emricasan, showed a beneficial role in liver inflammation and fibrosis in NASH mice by decreasing the expression of IL-1β and IL-18 and inactivating HSCs (131, 132).